The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).
David Raymond Ferry
Honoraria - Sanofi
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Bayer; Celgene; Roche; Sanofi
Roberto Bordonaro
No relevant relationships to disclose
Salvatore Siena
No relevant relationships to disclose
Filippo Pietrantonio
Consultant or Advisory Role - Merck; Roche; Sanofi
Honoraria - Roche
Stefan Bauer
No relevant relationships to disclose
Julien Taïeb
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Pascale Garreau-Laporte
Employment or Leadership Position - Sanofi
Sandrine Brette
Employment or Leadership Position - Sanofi
Emmanuelle Dochy
Employment or Leadership Position - Sanofi
Gérard Lledo
No relevant relationships to disclose